Spravato® (esketamine) is a newer pharmaceutical that was approved by the United States Food and Drug Administration (FDA) in 2019, to be delivered in a clinical setting as a nasal spray along with an oral antidepressant. As a depression medication,…
Andrew SchatzbergFebruary 24, 2025

Valant Revamps Its Healthcare Software, Sees Significant Growth
The hidden costs of managing prospective patients and mitigating those costs have a direct impact on the success of a behavioral healthcare practice.